Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2050 in Proliferative Lupus Nephritis or IgA Nephropathy
CTR20232195Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemircopan in lupus nephritis (LN), IgA nephropathy (IgAN), sponsored by Alexion Pharmaceuticals. Started Jul 2023; status: terminated.
02
Drugs
vemircopan
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20232195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232195.